Cardioprotective effects of exenatide against oxidative stress-induced injury

Chang,Guanglei; Zhang,Dongying; Yu,Hui; Zhang,Peng; Wang,Ying; Zheng,Aihua; Qin,Shu

doi:10.3892/ijmm.2013.1475

Cardioprotective effects of exenatide against oxidative stress-induced injury

Authors:
- Guanglei Chang
- Dongying Zhang
- Hui Yu
- Peng Zhang
- Ying Wang
- Aihua Zheng
- Shu Qin
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: August 27, 2013 https://doi.org/10.3892/ijmm.2013.1475
Pages: 1011-1020

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myocardial ischemia/reperfusion (MI/R) leads to oxidative stress, which may in turn lead to myocardial injury. In the present study, we investigated the effects of exenatide, a glucagon-like peptide-1 (GLP-1) analogue, on oxidative stress-induced injury in vitro and in vivo. In in vitro experiments, H9c2 cells were incubated with exenatide to determine the direct cytoprotective effects of exenatide following exposure to hydrogen peroxide (H2O2). Pre-treatment with exenatide (1 nM), prior to H2O2 exposure, increased cell viability and inhibited H2O2‑induced reactive oxygen species (ROS) production. Exenatide also decreased the levels of lactate dehydrogenase (LDH) and creatine kinase‑MB (CK‑MB) in the cultured supernatants, as well as those of malondialdehyde (MDA) in the H9c2 cells and increased the total superoxide dismutase (T‑SOD) levels in the H9c2 cells. In in vivo experiments, an animal model of MI/R was induced by coronary occlusion. Pre-treatment with exenatide (10 µg/kg/day) protected the rat hearts from MI/R-induced injury by decreasing the levels of LDH and CK‑MB in plasma, increasing the levels of catalase, T-SOD and glutathione peroxidase (GSH-Px) in the heart and decreasing the MDA levels in the rats with MI/R-induced injury. Exenatide also reduced the infarct size and enhanced cardiac function in the rats with MI/R-induced injury. Moreover, pre-treatment with exenatide inhibited cardiomyocyte apoptosis, increased Aktserine473 and Badserine136 phosphorylation and decreased cleaved caspase‑3 expression in vitro and in vivo; however, these effects were attenuated by the phosphoinositide 3-kinase (PI3K) inhibitor, LY294002. Our results suggest that exenatide exerts significant cardioprotective effects against oxidative stress-induced injury in vitro and in vivo. The mechanisms involved may be attributed to the scavenging of oxidative stress products, such as ROS, the increase in the concentrations of antioxidant defense enzymes and the inhibition of cardiomyocyte apoptosis. The anti‑apoptotic effects of exenatide were, at least in part, associated with the activation of the PI3K/Akt signaling pathway.

View Figures

View References

1	Acar E, Ural D, Bildirici U, Sahin T and Yılmaz I: Diabetic cardiomyopathy. Anadolu Kardiyol Derg. 11:732–737. 2011.
2	Zweier JL and Talukder MA: The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 70:181–190. 2006. View Article : Google Scholar : PubMed/NCBI
3	Zhao ZQ: Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol. 4:159–165. 2004. View Article : Google Scholar : PubMed/NCBI
4	Gottlieb RA: Cell death pathways in acute ischemia/reperfusion injury. J Cardiovasc Pharmacol Ther. 16:233–238. 2011. View Article : Google Scholar : PubMed/NCBI
5	Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G and Anversa P: Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 74:86–107. 1996.PubMed/NCBI
6	Palojoki E, Saraste A, Eriksson A, Pulkki K, Kallajoki M, Voipio-Pulkki LM and Tikkanen I: Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol. 280:H2726–H2731. 2001.PubMed/NCBI
7	Garber AJ: Novel GLP-1 receptor agonists for diabetes. Expert Opin Investig Drugs. 21:45–57. 2012. View Article : Google Scholar : PubMed/NCBI
8	Davidson JA: Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med. 76(Suppl 5): S28–S38. 2009. View Article : Google Scholar : PubMed/NCBI
9	Lorber D: GLP-1 receptor agonists: effects on cardiovascular risk reduction. Cardiovasc Ther. Jul 30–2012.(Epub ahead of print).
10	Mundil D, Cameron-Vendrig A and Husain M: GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res. 9:95–108. 2012. View Article : Google Scholar : PubMed/NCBI
11	Chiquette E, Toth PP, Ramirez G, Cobble M and Chilton R: Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers. Vasc Health Risk Manag. 8:621–629. 2012.PubMed/NCBI
12	Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G and Hoefer IE: Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 53:501–510. 2009. View Article : Google Scholar : PubMed/NCBI
13	Laviola L, Leonardini A, Melchiorre M, Orlando MR, Peschechera A, Bortone A, Paparella D, Natalicchio A, Perrini S and Giorgino F: Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology. 153:5770–5781. 2012. View Article : Google Scholar
14	Ravassa S, Zudaire A, Carr RD and Díez J: Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol. 300:H1361–H372. 2011. View Article : Google Scholar : PubMed/NCBI
15	Younce CW, Burmeister MA and Ayala JE: Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a. Am J Physiol Cell Physiol. 304:C508–C518. 2013. View Article : Google Scholar
16	Kumar S, Kain V and Sitasawad SL: High glucose-induced Ca²⁺ overload and oxidative stress contribute to apoptosis of cardiac cells through mitochondrial dependent and independent pathways. Biochim Biophys Acta. 1820:907–920. 2012.
17	Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E and Ganz W: Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J. 101:593–600. 1981. View Article : Google Scholar
18	Loesser KE, Kukreja RC, Kazziha SY, Jesse RL and Hess ML: Oxidative damage to the myocardium: a fundamental mechanism of myocardial injury. Cardioscience. 2:199–216. 1991.PubMed/NCBI
19	Suzuki K, Murtuza B, Sammut IA, Latif N, et al: Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation. 106:I270–I276. 2002.
20	Peng X and Li Y: Induction of cellular glutathione-linked enzymes and catalase by the unique chemoprotective agent, 3H-1,2-dithiole-3-thione in rat cardiomyocytes affords protection against oxidative cell injury. Pharmacol Res. 45:491–497. 2002. View Article : Google Scholar
21	Li C, Liu Z, Tian J, Li G, Jiang W, Zhang G, Chen F, Lin P and Ye Z: Protective roles of Asperosaponin VI, a triterpenesaponin isolated from Dipsacusasper Wall on acute myocardial infarction in rats. Eur J Pharmacol. 627:235–241. 2010. View Article : Google Scholar : PubMed/NCBI
22	Li J, Shao ZH, Xie JT, Wang CZ, Ramachandran S, Yin JJ, Aung H, Li CQ, Qin G, Vanden Hoek T and Yuan CS: The effects of ginsenoside Rb1 on JNK in oxidative injury in cardiomyocytes. Arch Pharm Res. 35:1259–1267. 2012. View Article : Google Scholar : PubMed/NCBI
23	Jin HB, Yang YB, Song YL, Zhang YC and Li YR: Protective roles of quercetin in acute myocardial ischemia and reperfusion injury in rats. Mol Biol Rep. 39:11005–11009. 2012. View Article : Google Scholar : PubMed/NCBI
24	Cai Y, Hu X, Yi B, Zhang T and Wen Z: Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression. Mol Biol Rep. 39:10705–10711. 2012. View Article : Google Scholar : PubMed/NCBI
25	Fontes JP, Gonçalves M and Ribeiro VG: Serum markers for ischemic myocardial damage. Rev Port Cardiol. 18:1129–1136. 1999.(Portuguese).
26	Xie Y, Wang SX, Sha WW, Zhou X, Wang WL, Han LP, Li DQ and Yu DM: Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Clin Med J. 121:2134–2138. 2008.PubMed/NCBI
27	Chinda K, Chattipakorn S and Chattipakorn N: Cardioprotective effects of incretin during ischaemia-reperfusion. Diab Vasc Dis Res. 9:256–269. 2012. View Article : Google Scholar : PubMed/NCBI
28	Khalil PN, Neuhof C, Huss R, Pollhammer M, Khalil MN, Neuhof H, Fritz H and Siebeck M: Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol. 528:124–131. 2005. View Article : Google Scholar
29	Hausenloy DJ and Yellon DM: New directions for protecting the heart against ischaemia-reperfusion injury: targeting the reperfusion injury s alvage kinase (RISK)-pathway. Cardiovasc Res. 61:448–460. 2004. View Article : Google Scholar : PubMed/NCBI
30	Mullonkal CJ and Toledo-Pereyra LH: Akt in ischemia and reperfusion. J Invest Surg. 20:195–203. 2007. View Article : Google Scholar : PubMed/NCBI
31	Fujio Y, Nguyen T, Wencker D, Kitsis RN and Walsh K: Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 101:660–667. 2000.PubMed/NCBI
32	Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, Force TL, Franke TF, Hajjar RJ and Rosenzweig A: Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 104:330–335. 2001. View Article : Google Scholar : PubMed/NCBI